Register now for 600! Get your conference guide & latest schedule | See you in Singapore on 9 22-23, 2026BPD
2026BPD Singapore is launching soon! Registration has already surpassed 600, with 60+ speakers confirmed!Site ConfigurationTechnical Forum、Closed-door meeting、BPD & XDC Gala Dinner、BPD MATCH 1-on-1 MeetingMulti-faceted sessions focusing on Southeast Asian manufacturing capacity collaboration, market access, and regional compliance. We bridge Chinese pharmaceutical companies and suppliers with Southeast Asian peers to capitalize on the strategic window for expanding into Southeast Asia.Conference agenda and outline updated. Please check the participant guide!
⏰️Time:2026-9-22 to 23, 2026
⏰️Location:Marina Bay Sands Singapore Convention & Exhibition Centre
Register for limited free tickets before 9/21!
Attendee Guide
● Date
2026-9-22 to 23, 2026
● Check-in Time (Singapore Time)
Exhibitor Check-in: 7:00 Start check-in
Audience Check-in: 8:00 Start
● Meeting Location:
Singapore Marina Bay Sands Convention Centre, Heliconia Junior Ballroom 3411-3513
Heliconia Junior Ballroom 3411-3513, Sands Expo & Convention Centre, Singapore
● Ticket Confirmation:
Scan the QR code below to enterMy TicketsView your check-in QR code and ticket details. Attendees must present this at the event venue.QR codeand verify your information at the check-in desk to receive it.Representative IDEntry permitted only after this.
Friendly Reminder:To reduce wait times, arrive before 8:45 and avoid peak hours.
● Transportation & Accommodation Guide:
Schedule & Outline Update
Schedule updated through 9/15...
9/21
18:00-20:00BPD & XDC Gala Dinner
9/22 AM Session 1
BPD Plenary Forum
Global Vision: Biopharmaceutical Supply Chain Restructuring and Process Ecosystem Collaboration
09:00-09:05Welcome
Speaker:Vera Deng, Enmore BIO, Founder & CEO
09:05-09:10Opening Remarks
Speaker:Jimmy Li, WuXi XDC, CEO
09:10–09:40Dialogue: A New Paradigm for Globalizing China's Biopharmaceuticals: From Process Innovation to Ecosystem Collaboration
Moderator:Vince Deng, OnTargetBio, CFO
Panelist:Jimmy Li, WuXi XDC, CEO
09:40–10:20Panel Discussion: Cross-Border Synergy and Bilateral Co-Development: China Going Global and the Southeast Asian Industrial Ecosystem Amid Global Supply Chain Restructuring
Panelist:Jimmy Li, WuXi XDC, CEO
Bo Ying, Abogen Biosciences, CEO
Aimin Hui, EnCureGen Pharma, Founder, Chairman & CEO
Xiaoliang Sang, Cytiva, VP
Gang Qin, GeneQuantum, CEO
10:20–10:50Tea Break & Networking
Regional Deep Dive: Asia Strategy to Southeast Asia Execution
10:50–11:10Keynote Speech: Strategic Framework and Practical Roadmap for Chinese Pharmaceutical Companies Entering the Southeast Asian Market
Speaker:Clement YauTemasek Lifesciences Accelerator, VP, Investments
11:10-11:30Keynote Speech: Commercial Effectiveness for Biopharmaceuticals Entering ASEAN
Speaker:Shri Sarkar, L.E.K. Consulting, Partner
11:30–12:10Panel Discussion: From Partnership to Value Co-Creation – Practical Challenges and Breakthrough Solutions for Cross-Border Pharmaceuticals in China and Southeast Asia
Moderator:Clement YauTemasek Life Sciences Accelerator, VP, Investments
Panelist:Lawrence, Rxilient, CEO
Pengfei Chen, EDB, VP
Shri Sarkar, L.E.K. Consulting, Partner
12:00-13:00 Lunch & Networking
9/22 PM Session 1
Novel Molecules and Innovative Therapeutics
XDC
13:00-13:20 Keynote: Enabling Next-Generation Bioconjugates – Integrated CMC Strategies for AOC and APC Development
Speaker:Rui Wu, WuXi XDC
13:20-13:40Keynote: One Development Program, Three Key Markets: Regulatory and CMC Strategies for Global ADC Success
Speaker:Gani Du, WuXi XDC, Senior Director, Head of Regulatory Affairs
13:40-14:00Keynote Address: Regulatory Considerations for ADC Manufacturing and Controls
Speaker:Audrey Jia, ex-FDA OBP CMC reviewer; Founder of Wonderfulland Regulatory Consulting
Outline
1. The complexity of the ADC manufacturing process necessitates elevated CMC considerations from a regulatory perspective.
2. Leveraging Platform Technology to Accelerate CMC Development
3. CMC Readiness Is Critical for Success in Expedited Regulatory Pathways
BsAb-TCE
14:00-14:20Keynote: Unlocking Recent Clinical Advances in mRNA-Based Cancer Vaccines and B-Cell Depletion Therapies
Speaker:Bo Ying, Abogen Biosciences, CEO
14:20-14:40Keynote Speech: Mabwell's External Innovation Strategy: Building Nexuce Therapeutics to Advance T-Cell Engagers for Solid Tumors
Speaker:Michelle Liu, Mabwell Bioscience, Deputy Director of External Innovation
Nexuce Therapeutics is developing the next generation of T-cell engagers. Our proprietary Sterimask™ and ConCos™ platforms enable strictly tumor-associated antigen (TAA)-dependent activation with sustained cytotoxicity, unlocking a significantly broader therapeutic window for solid tumors.
14:40-15:00 Tea break & Networking
XDC & BsAb-TCE: Global Development and Regulatory Compliance
15:00-16:00Panel Discussion: XDC & TCE Innovation: Balancing Molecular Design, CMC Implementation, and Accelerated Global Development
Moderator:Jason Li, Trinomab Pharmaceutical, SVP & Global CMC Head
Panelist:Mengqi Fan, Nexuce Therapeutics, COO
Audrey Jia, ex-FDA OBP CMC reviewer; Founder of Wonderfulland Regulatory Consulting
Yuhua Hu, Vice President and Head of XDC US & EU CMC, WuXi XDC
Thierry Menguy, Adcytherix, CDO
Cell Therapy
16:00- 16:40 Panel Discussion: Global Development and Innovation Opportunities in Cell Therapy
Moderator:Peter Chen, Astar, Commercial and Strategy Lead
Panelist:Xiaoming Peng, Lion TCR, CEO
Ke Zhang, SCG Cell Therapy, Chief Strategy Officer
Yen CHOO, NTU, Lee Kong Chian School of Medicine, Associate Professor of Stem Cell Science and Regenerative Medicine
Sai Kiang Lim, Paracrine Therapeutics, Research Director
16:40-17:00Keynote Speech: Design of In Vivo Cell Engineering Constructs
Speaker:Ke Zhang, SCG Cell Therapy, Chief Strategy Officer
17:00-17:20 Keynote Address: Global Registration and Strategic Deployment of Innovative iPSC Cell Therapies
Speaker:Xin (Richard) Yuan, Hopstem Biopharmaceutical, Vice President of Quality
17:20-17:40Keynote: Engineering iPSCs for Efficient Cell Therapy Manufacturing at Industrial Scale
Speaker:Yen CHOO, NTU, Lee Kong Chian School of Medicine, Associate Professor of Stem Cell Science and Regenerative Medicine
17:40-18:00Keynote Speech: From Discovery to Therapeutics: Biological Advances Driving the Clinical Translation of MSC-sEVs
Speaker:Sai Kiang Lim, Paracrine Therapeutics, Research Director
9/22 PM Session 2
Regulations and Market Access in Southeast Asia
Malaysia
13:00-13:20Keynote Address: Overview of Malaysia's Pharmaceutical Regulatory Policies
Speaker:Zaril Harza Zakaria, NPRA, Head of Investigational Product Evaluation and Safety Section
13:20-13:40Dialogue: Key Regulatory Compliance Points in Malaysia
Speaker:Billy Urudra, MOPI, Executive Director
Zaril Harza Zakaria, NPRA, Head of Investigational Product Evaluation and Safety Section
Indonesia
13:40-14:00 Keynote Speech: Indonesia's Evolving Pharmaceutical Landscape: Regulatory Readiness and Market Access for Innovative Therapies
Speaker:Shanti Marlina Sibuea, BPOM, Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control
14:00-14:20Keynote Address: To Be Confirmed
Speaker:Vino Soaduon Hamonangan, Etana, Production Director
14:20-14:40Dialogue: The New Landscape of Innovative Biopharma Review in Southeast Asia: From Regulatory Framework to Corporate Implementation
Panelist:Shanti Marlina Sibuea, BPOM, Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control
Vino Soaduon Hamonangan, Etana, Production Director
Outline
1. NewTechnical Standards for CMC Assessment of Innovative Complex Biologics
2. Regulatory harmonization, reliance, joint assessment, and selected mutual recognition mechanisms.
3. How pharmaceuticals align early-stage CMC development with Indonesian regulations to reduce remediation costs at submission.
14:40-15:00Tea Break & Networking
Thermo Fisher Session
Powering Results in Upstream Bioprocessing: From Stable Cell Lines to Scalable Manufacturing
15:00-15:30Keynote Speech: Engineering Selection Pressure and Gene Integration Strategies to Accelerate Stable CHO Cell Line Development
Speaker:Garima Mishra, Thermo Fisher Scientific, Field Applications Scientist Manager, Cell Culture / Cell Therapy, APJ
15:30-16:00 Keynote Address: The Next Generation of Hydrolysates: Functionally Defined Yeast Extract for CHO-Based Therapeutics and Halal-Certified Peptone for Biologics Development and Manufacturing
Speaker:Chye Boon, Thermo Fisher Scientific, Global Senior Manager, Business Development, Supplements, Bioproduction Group
16:00-16:30 Keynote: Smarter Cell Culture Media & Process Development: From High-Throughput Screening and AI for Media Optimization to Raw Material Control and Format Economics
Speaker:Gunjan Bajaj, Thermo Fisher Scientific, Senior Technical Business Development Manager, APJ Bioproduction Group
16:30-17:00Keynote Speech: Accelerating the Path to Commercialization with Single-Use Bioreactors
Speaker:Colin DiPaola, Thermo Fisher Scientific, Senior Director, Product Design and Operations
9/22 PM Session 3
Closed-door meeting
China–Southeast Asia Cross-Border Biopharma Cooperation
Moderator: H. Fai Poon, CEO, Sirnaomics
15:00-15:20Dialogue: Singapore's Biopharma Ecosystem: Driving Development, Scale-Up, Regulatory Pathways, and Global Market Access
Panelist:Teo Junxiong, HSA, Director of Partnerships and Ecosystem Development
Pengfei Chen, EDB, VP
Koh Boon Tong, Bioprocessing Technology Institute (BTI), Executive Director
15:20-15:35Guest Representative Sharing Session
Speaker:Jimmy Li, WuXi XDC, CEO
Billy Urudra, MOPI, Executive Director
Shanti Marlina Sibuea, Badan POM, Acting Director
15:35-16:30Open Discussion
Reference Discussion Topics
What cooperation models are available?
What is the most critical factor when selecting partners?
How do you balance policy frameworks and industrial ecosystems when selecting overseas expansion locations?
Guest List:
Victor Li, Eximmium, CEO
H. Fai Poon, Sirnaomics, CEO
SHAN Yongqiang, Biotech Co., Ltd. CEO
Vince Deng, Med-Fine Capital, Partner
Wendy Zhang, PFP Capital Limited, CIO
Qiuming (Miles) Shi, PT Etana Biotechnologies Indonesia, CTO
Billy Urudra, Malaysian Organisation of Pharmaceutical Industries, Executive Director
Jason Li, Zhuhai Trinomab Pharmaceutical Co., Ltd. SVP, Global CMC Head
Liu Dou, Shenzhen Oralead PharmaCo., Ltd.CEO
Alex Gavryushkin, Fold AI, Founder & CEO
Clement Yau, Temasek Lifesciences Accelerator, Vice President
Chen Pengfei, EDB, VP
Piong Teck Onn, Kotra Pharma (M) Sdn Bhd, Managing Director
Lipeng Lai, xtalpi, Co-founder and Chief Innovation Officer at XtalPi
Girisan Kariangal, A. Menarini Asia Pacific, Vice President
Billy Urudra, Malaysian Organisation of Pharmaceutical Industries, Executive Director
Shanti Marlina Sibuea, Badan POM, Act. Director
Dr. Zaril Harza Zakaria, National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia, Head of Section for Investigational Products in Clinical Trials
Yuankai Wang, Twain Therapeutics, Vice President of Antibody Discovery & Development
Veerachat Petpisit, Nouvogenes Therapeutics, CEO
Waqas Atiq, Novugen Pharma, SVP, Business Development
Gaurav Arora, BioPharma Centrum, Chief Commercial Officer
Lalit Baregama, Symbiotec Pharmalab, Chief Business Officer
Yiwei Wang, Biocity Biopharmaceuticals, CSO
Georges Dagher, GSK, VP MCL
Jun Feng, Johnson & Johnson, APAC Market Access Director
9/23 AM Session 1
AI for Pharmaceuticals
09:00-09:20 Keynote Speech: Harnessing Organoids and AI for Next-Generation Targeted Drug Discovery
Speaker:Learning Card, Signet Therapeutics, Business Development Director
Outline
1.Developing, the World's First Clinical-Stage Targeted Therapy for Diffuse Gastric Cancer via a Proprietary AI + Organoids Platform
2.Accelerating Target Discovery and Drug Development Using Organoid Models and AI-Driven Drug Design
09:20-09:40Keynote: AI Applications in Molecular Design and Target Discovery
Speaker:Lipeng Lai, XtalPi, Co-Founder & CIO
Outline: 1. Demonstrating the critical role of the dry-wet integration loop in pharmaceutical innovation, with examples from peptide and siRNA drug discovery. 2.Discuss Applying AI in biology—particularly virtual cells.
09:40-10:00 Keynote: Shipping AI When Hallucinations Are Not an Option
Speaker:Theo Palios, Unicorn Labs, CEO
Outline: Our Journey from a Coin-Toss Model to a Hospital-Deployed Screening System Across Three Iterations - Starting with a basic machine learning model - Evolving into an Agentic System featuring independent LLMs working in parallel - Culminating in the Harness platform Plus: How to implement a Harness like ours for other critical sectors, such as healthcare and banking.
10:00-10:20 Keynote Speech: High-Quality Data-Driven Agent for Protein Design
Speaker:Mingchen Li, Matwings Technology, Chief Scientist, AI Lab
Outline
1.Constructionof the Protein Data Governance System
2.Introduction to Protein AI Models
3.Protein Design Agent 4.Application Cases
10:20-10:50Tea Break & Networking
10:50-11:10 Keynote Speech: Regulatory Compliance for AI in Pharmaceutical R&D
Speaker:Peter Luo, Adagene, Chairman, CEO & President of R&D
11:10-11:30 Keynote: Challenges in Implementing Biopharmaceutical CMC Operations
Speaker:Jason LiTrinomab Pharmaceutical, SVP & Global CMC Head
Outline: Although AI is deeply integrated into our daily lives and work, deploying it in pharmaceutical CMC operations remains exceptionally challenging due to the industry's stringent regulatory standards, inadequate data infrastructure, and issues with black-box models and hallucinations. Understanding these limitations will enable effective AI adoption in specific areas—such as unit operation modeling, data analysis, documentation management, and risk assessment—where AI can serve as a powerful tool to accelerate workflows.
11:30-11:50 Keynote: The AI Commercial Loop – Beyond Corporate Data Theater
Speaker:Andres von der Walde, Novo Nordisk, Sr. Director – Customer Engagement & Capabilities APAC
12:00-13:00Lunch & Networking
9/23 PM Session 1
Advanced Technology
13:00-13:40 Panel Discussion: Deep Dive into Southeast Asia – Breaking Silos Across Regulation, Manufacturing, Medical Affairs, and Commercialization
Moderator:Lim Fu Chin, First Asian mRNA Manufacturing Facility, Associate Director of Digitalization
Panelist:Poh Jeff, Gilead, Regulatory Affairs CMC Lead
Girisan Kariangal,Menarini APAC, Vice President
Georges Dagher, GSK, VP MCL
Andres von der Walde, Novo Nordisk, Sr. Director – Customer Engagement & Capabilities APAC
13:40-14:00 Keynote Speech: Regulatory CMC Considerations for Biologics Technology Transfer
Speaker:Poh Jeff, Gilead, Regulatory Affairs CMC Lead
14:00-14:20Keynote Speech: Toolbox Strategies for Bispecific Antibody Purification
Speaker:Wei Zhang, BTI, Principal Scientist & Group Leader, Downstream Processing
Outline
1. High format diversity and structural complexity complicate bispecific antibody purification.
2. Each bsAb format presents unique purification challenges, and no single platform suits all formats.
3. A flexible toolbox approach is essential for robust and efficient bispecific antibody purification.
14:20-14:40 Keynote Speech: Risk-Based Maintenance Change Control to Meet Global Pharmaceutical Audit Standards
Speaker:Joey Low, Novartis, Senior Maintenance Engineer
14:40-15:00Keynote: Advancing Drug Products Through Innovation, Devices, and Manufacturing as One DP
Speaker:Jeremy GuoWuXi Biologics, Senior Vice President, Head of Global Drug Product Operations
15:00-15:20 Keynote: Beyond Grade A: Building Intelligent Aseptic Fill-and-Finish Facilities
Speaker:Leon Cruz, son of Francis Cruz, Duopharma, Head of Production
Outline: Integrating barrier technology, automation, real-time monitoring, and digital systems to enhance sterility assurance, regulatory compliance, and operational performance
15:20-15:40 Keynote Address: Advanced Non-Viral Dumbbell-Shaped DNA Vectors for Genetic Therapy and Vaccination
Speaker:Volker Patzel, NUS/AVECRIS, Founder, Chief Scientific Officer, Chairman
15:40-16:00 Keynote Speech: A Virtual CHO Cell Model for Tunable-Precision Cellular Control
Speaker:Song Yuan, ChemT, Associate Director
Outline
1.AI-guided cell line engineering for faster optimization of growth, productivity, and quality.
2.Virtual cell-derived small molecules to precisely tune cellular functions and states.
9/23 AM Session 2
Southeast Asia Cooperation Opportunities
09:00-09:40Panel Discussion: Southeast Asia Focus: How Innovative Biotechs Maximize R&D, Manufacturing, and Business Development Collaboration
Moderator:Andy Siow, Luye Pharma (Malaysia), Vice President APAC
Panelist:Lalit Baregama, Symbiotec Pharmalab, CBO
Vince Deng, Med-Fine Capital, Partner
Vijay P. Karwal, CBC Group, Managing Director
09:40-10:20Panel Discussion: Regulation and Market Access for Biologics in Singapore and Southeast Asia
Moderator:Jin Shun, PharmaGend, Managing Director
Panelist:Jun Feng, J&J, APAC Market Access Director
Daniel Lee, Menarini APAC, Head of Commercial
Jun Hu, WuXi XDC, Head of Client Center of Excellence & Head of Singapore Site Management
Michelle Dee, MSD, Director - Medical Excellence, Global Scientific Content & Medical Information
10:20-10:50 Tea break & Networking
10:50-11:10Keynote Speech: Beyond Approval: Four Market Access Decisions That Determine Commercial Success in Southeast Asia
Speaker:Jun Feng, J&J, APAC Market Access Director
Outline: 1. Why market access should start before regulatory approval.2. How to choose the right product and market-entry strategy for Southeast Asia.3. What capabilities companies need to build sustainable regional success.
India
11:10-11:25Keynote Address: Geopolitics, Supply Chains, and Market Access: Building a Resilient Biopharma Policy for India
Speaker:Gaurav Arora, BioPharma Centrum, Chief Commercial Officer
11:25:11:40Dialogue: Regulatory pathways for biologic approval in India
Panelist:Gaurav Arora, BioPharma Centrum, Chief Commercial Officer
Lalit Baregama, Symbiotec Pharmalab, CBO
Thailand
11:40-12:00Keynote Speech: Scaling Gene Therapy Commercialization Beyond the U.S. and Europe: Insights from Thailand
Speaker:Veerachat Petpisit, Nouvogenes Therapeutics, Founder
12:00-13:00Tea Break & Networking
9/23 PM Session 2
Small Nucleic Acids / Peptides / mRNA / Gene Therapy
13:00-13:20Keynote Speech: Superior Extrahepatic Delivery via the PNP Platform and Clinical Applications
Speaker:H. Fai Poon, Sirnaomics, CEO
Outline
1. Advantages of the PNP platform for siRNA delivery.
2. Clinical data for local fact reduction to validate the PNP platform
13:20-13:40Keynote: Synthesis and GMP Manufacturing of Cyclic and Modified Peptides
Speaker:Yusheng Sui, Shenzhen Oralead Pharma, VP of R&D
Outline
1. Technical Accumulation and Development Prospects of Oral Peptides
2. Competitive Analysis of Global Technology Platforms for Oral Peptides
3. Our Competitive Advantages and Pipeline Strategy in This Field
13:40-14:00Keynote Speech: Rethinking Manufacturing Architecture for Personalized Medicine – From CRISPR Gene Editing to Personalized Cancer Vaccines
Speaker:Veerachat Petpisit, Nouvogenes Therapeutics, Founder
Outline: Achieving Economies of Scale in Personalized Medicine – Balancing Centralization and Decentralization in Manufacturing – The Platform Approach to Future Treatment Personalization
14:00-14:20Keynote: AI Meets mRNA at enCureGen
Speaker:Aimin Hui, EnCureGen Pharma, Founder, Chairman & CEO
14:20-14:40Keynote Speech: Implementing Soft Sensors in Fermentation Processes: A Practical Approach to Real-Time Monitoring and Process Optimization
Speaker:Junita Dwi Andhini, Bio Farma, QA Engineer
14:40-15:00 Keynote Speech: Innovations in Science and Technology for the Benefit of Humanity – Gritgen Therapeutics Inc is dedicated to developing high-quality, innovative gene therapy drugs that are affordable.
Speaker:Claire Zhang, Gritgen, CTO
15:00-15:20 Keynote: Harnessing Cell Surface Glycans for Therapeutics
Speaker:Andre Choo, BTI, A*STAR, Deputy Executive Director
15:20-15:40Keynote Speech: Competitive Landscape and Future Outlook for Brain-Penetrating Nucleic Acid Delivery Technologies
Speaker:Tinghe Wu, P.S.K. Biosciences, CEO
Outline
1. Frontiers in Brain-Targeted Delivery Technologies
2. Extrahepatic Delivery of Nucleic Acid Therapeutics
3. Engineered Exosome Technologies for Brain-Targeted Nucleic Acid Delivery
15:40-16:00Keynote Speech: PEG-free LNPs for Targeted Delivery of mRNA Vaccines
Speaker:YiYan, BTI, A*STAR, Distinguished Principal Scientist
16:00-16:20 Keynote Address: Weight Management with 2.0 and Beyond: Monthly Efsubaglutide Alfa and a Novel Dual-Target Metabolic Pipeline
Speaker:Michael Zhang, Innogen Pharmaceuticals, Head of Regulatory Affairs
Outline: A potent GLP-1 asset delivering significant fat loss with muscle preservation, featuring a dosing profile convenient enough for monthly administration. A broad, forward-looking metabolic pipeline spanning multiple targets and formulations. Our dual-action approach—combining neuroprotection and inflammation control—creates a cleaner translational narrative from pathology to cognition. Accelerating global commercialization by expanding partnered territories while strengthening market performance.